mounjaro tirzepatide patent expiration us Lilly's new drug (tirzepatide ) wins FDA approval In weight loss battle, Novo

The GLP-1 segment recorded 177% sales growth on a moving annual turnover basis to 1,446 crore in February 2026, with Eli Lilly's Mounjaro retaining its position as India's best-selling drug for the fifth consecutive month at 117 crore in February sales

The peptide binds to vascular endothelial growth factor receptor 2 (VEGFR2), triggering Akt-eNOS signaling that increases nitric oxide production in blood vessel cells

They can enhance your bodys natural processes and provide additional support for your weight management journey, without requiring a medical consultation

Patients with a personal or family history of medullary thyroid carcinoma should not take semaglutide, as animal studies have shown an association between GLP-1 agonists and thyroid C-cell tumors

Recent research found people who took semaglutide and had no prior history of suicidal ideation were four times less likely to experience suicidal thoughts compared to those taking a non-GLP-1

Umbrella Labs is also highlighting retatrutide as a complementary research tool for multi pathway endocrine signaling designs where amylin receptor system outputs are evaluated alongside other peptide responsive receptor families using shared controls and matched documentation standards